Published in Managed Care Weekly Digest, May 30th, 2005
Sirolimus, a substance that is thought to help prevent reclosure of coronary arteries, can be released from certain types of stents to greatly reduce the need for target-vessel revascularization (TVR) compared with bare-metal stents (i.e., stents without medication).
These drug-eluting stents have the potential to further improve long-term clinical outcome after primary percutaneous coronary intervention (PCI), such as angioplasty. However, the lack of randomized trials to assess...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Weekly Digest
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.